ArticleBMC cancer2025

Comparative safety of nivolumab plus ipilimumab versus nivolumab plus relatlimab in advanced melanoma: a pharmacovigilance study based on the FDA adverse event reporting system (FAERS).

Shanshan Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.